背景:同性恋,双性恋,在美国,与艾滋病毒感染者(GBMSM-LWH)发生性关系的其他男性承受着细菌性性传播感染(STIs)的沉重负担。及时诊断和治疗是预防的关键。只有少数研究将用于细菌STI筛查的家庭标本自收集与现场音频和视频(AV)会议相结合。没有人专注于GBMSM-LWH或纳入动机性访谈(MI),以客户为中心,基于优势的咨询方法,旨在支持个人创造积极的行为改变。
目的:我们的研究旨在调查基于MI的远程健康干预的可行性和可接受性,该干预将通过现场AV会议从可能暴露和MI的不同解剖部位进行家庭标本自我收集,以使性活跃的GBMSM-LWH参与细菌STI筛查。
方法:通过移动约会应用程序和社交网站上的广告以及通过同行推荐,从美国各地招募参与者。第一阶段涉及向75GBMSM-LWH提供创新的远程健康干预措施,用于细菌STI筛查。我们的干预措施包括三个组成部分:(1)预先测试现场AV会议,包括MI指导的讨论,以引起对细菌性传播感染的认识;填补任何知识空白;增强定期检测淋病的重要性,衣原体,和梅毒;并建立自我效能以进行标本自我收集;(2)通过邮寄尿液样本进行家庭自我收集和返回(用于淋病和衣原体检测),喉咙拭子(用于淋病和衣原体检测),直肠拭子(用于淋病和衣原体检测),和手指刺血样本(用于梅毒测试);(3)测试后现场AV会议,包括MI指导的讨论,以准备参与者接受测试结果,并制定个性化的行动计划寻求治疗(如果有必要)和重复测试。将计算描述性统计和进展比率,我们的干预的可行性和可接受性的潜在变化将被数字总结和图形可视化。第二阶段包括阐明态度,主持人,以及与通过半结构化的深入访谈参与每个干预组件有关的障碍,该访谈由20名参与者组成,这些参与者完成了预测试的逐渐较小的子集,细菌STI测试的样本返回,和后测会议。主题分析将用于确定,分析,并报告数据中的模式。定量和定性数据将在设计时整合,方法,解释,和报告水平。
结果:研究程序于2023年9月由密歇根大学的机构审查委员会批准。参与者招募于2024年4月开始。
结论:我们的研究将推进2021年至2025年美国性传播感染国家战略计划的多个目标,特别是与预防新的性传播感染有关的目标;加快性传播感染研究的进展,技术,和创新;并减少与性传播感染相关的健康差距。
背景:ClinicalTrials.govNCT06100250;https://www.临床试验.gov/研究/NCT06100250。
■DERR1-10.2196/64433。
BACKGROUND: Gay, bisexual, and other men who have sex with men living with HIV (GBMSM-LWH) in the United States bear a heavy burden of bacterial sexually transmitted infections (STIs). Timely diagnosis and treatment are key to prevention. Only a few studies have combined home specimen self-collection for bacterial STI screening with live audio and video (AV) conferencing. None have focused on GBMSM-LWH or incorporated motivational interviewing (MI), a client-centered, strengths-based counseling approach that seeks to support individuals to create positive behavioral change.
OBJECTIVE: Our study seeks to investigate the feasibility and acceptability of an MI-based telehealth intervention that integrates home specimen self-collection from different anatomical sites of possible exposure and MI delivered via live AV conferencing to engage sexually active GBMSM-LWH in bacterial STI screening.
METHODS: Participants are being recruited from across the United States via advertising on mobile dating apps and social networking sites and via peer referral. Phase 1 involves piloting the delivery of an innovative telehealth intervention for bacterial STI screening to 75 GBMSM-LWH. Our intervention includes three components: (1) a pretest live AV conferencing session involving an MI-guided discussion to elicit awareness of bacterial STIs; fill any knowledge gaps; bolster the perceived importance of regularly testing for gonorrhea, chlamydia, and syphilis; and build self-efficacy for specimen self-collection; (2) home self-collection and return via mail of a urine sample (for gonorrhea and chlamydia testing), a throat swab (for gonorrhea and chlamydia testing), a rectal swab (for gonorrhea and chlamydia testing), and a finger-stick blood sample (for syphilis testing); and (3) a posttest live AV conferencing session involving an MI-guided discussion to prepare participants for receiving test results and formulate personalized action plans for seeking treatment (if warranted) and repeat testing. Descriptive statistics and progression ratios will be calculated, and potential variations in our intervention\'s feasibility and acceptability will be numerically summarized and graphically visualized. Phase 2 involves elucidating attitudes, facilitators, and barriers related to engaging in each intervention component via semistructured in-depth interviews with a purposive subsample of 20 participants who complete progressively smaller subsets of the pretest session, specimen return for bacterial STI testing, and the posttest session. Thematic analysis will be used to identify, analyze, and report patterns in the data. Quantitative and qualitative data will be integrated at the design, methods, interpretation, and reporting levels.
RESULTS: Study procedures were approved by the Institutional Review Board at the University of Michigan in September 2023. Participant recruitment began in April 2024.
CONCLUSIONS: Our study will advance multiple goals of the STI National Strategic Plan for the United States for 2021 to 2025, specifically those pertaining to preventing new STIs; accelerating progress in STI research, technology, and innovation; and reducing STI-related health disparities.
BACKGROUND: ClinicalTrials.gov NCT06100250; https://www.clinicaltrials.gov/study/NCT06100250.
UNASSIGNED: DERR1-10.2196/64433.